Concentration-Driven Production in Turnover Models

Why Saturable Production Matters

A drug can change a biomarker gradually even when the drug concentration changes promptly. One explanation is that concentration modifies the rate at which the biomarker is produced, while the biomarker itself continues to disappear through first-order loss. If the production effect saturates, increasing concentration eventually yields diminishing increases in synthesis. This coupling of a saturable concentration effect to biomarker turnover determines both the eventual response and how quickly the biomarker approaches it.

The model below assumes that the drug concentration \(C(t)\) is available as an input, either measured or predicted from a pharmacokinetic model. It describes how that concentration affects biomarker production; it does not specify how the drug concentration changes over time.

With no drug effect, \(f(0)=0\), so the baseline equilibrium is \(R_0=k_{\mathrm{in},0}/k_{\mathrm{out}}\). The synthesis rate has units of biomarker concentration per unit time, whereas \(k_{\mathrm{out}}\) has units of inverse time. Thus the baseline production and loss rates balance at \(R_0\). This equilibrium assumption is important: if the biomarker is already drifting before drug exposure, its starting value need not equal the model’s baseline equilibrium.

Two Saturable Production Functions

The Emax function is a rectangular hyperbola:

The concentration \(EC_{50}>0\) is the concentration at which the drug-mediated change in synthesis reaches half its maximum. At \(C=EC_{50}\), \(f(C)=1/2\). As \(C\) increases without bound, \(f(C)\) approaches one, so synthesis approaches \(k_{\mathrm{in},0}(1+E_{\max})\). At concentrations much lower than \(EC_{50}\), \(f(C)\) is approximately \(C/EC_{50}\); at high concentrations, further increases in \(C\) have progressively smaller effects.

A sigmoid Emax function adds a Hill coefficient \(\gamma>0\):

This function also equals one-half at \(C=EC_{50}\), but \(\gamma\) controls the steepness around that concentration. When \(\gamma=1\), it reduces to the Emax function. A value above one produces a steeper transition, while a value below one produces a more gradual transition. The parameter \(\gamma\) changes the shape of the concentration-effect curve; it does not change its lower or upper limits.

For either function, \(f(C)\) lies between zero and one for nonnegative \(C\). Therefore, the production multiplier ranges between 1 and \(1+E_{\max}\). Inhibition requires \(E_{\max}\geq -1\) if production must remain nonnegative even at saturating concentration. In a particular application, the relevant requirement is that \(1+E_{\max}f(C(t))\geq 0\) throughout the concentration range being modeled.

Steady State and the Time Course

When concentration is held constant at \(C\), the production rate is constant. At steady state, the rate of change is zero, so production must equal loss:

Solving gives the concentration-specific equilibrium:

This result follows directly from the assumptions of constant concentration and first-order loss. It also shows why \(E_{\max}\) is defined as a fractional change in synthesis: under this model, the steady-state biomarker’s fractional change from baseline is the same, because the loss rate remains unchanged.

For a step to a constant concentration at time zero, the differential equation has a constant input and a first-order loss term. Subtract the steady-state equation from the time-dependent equation. The difference \(R(t)-R_{\mathrm{ss}}(C)\) then satisfies \(\frac{d}{dt}[R(t)-R_{\mathrm{ss}}(C)]=-k_{\mathrm{out}}[R(t)-R_{\mathrm{ss}}(C)]\). Solving this first-order equation yields:

If the biomarker starts at baseline, \(R(0)=R_0\). The response moves exponentially toward the new equilibrium, with a time constant \(1/k_{\mathrm{out}}\) and half-life \(\ln(2)/k_{\mathrm{out}}\). These describe the biomarker’s turnover response, not the time required for the drug concentration to change.

When concentration varies continuously, the same loss process weights earlier production effects less than more recent ones. Multiplying the differential equation by the integrating factor \(e^{k_{\mathrm{out}}t}\), integrating, and then dividing by that factor gives:

This expression makes explicit that \(R(t)\) depends on the history of concentration, not only its value at time \(t\). It is valid when the parameters are constant and the stated production and loss model applies over the interval.

Assumptions, Diagnostics, and Alternatives

The interpretation of the model depends on its assumptions. Concentration is treated as a known, appropriately aligned driver; synthesis responds to the current concentration through the selected function; loss is proportional to the current biomarker concentration with a constant \(k_{\mathrm{out}}\); and the baseline production and loss balance when \(C=0\). The model also treats the drug effect as acting on production only. A good numerical fit does not establish that each assumption is true.

Examine predictions and residuals over time, concentration, and dose. Persistent overprediction or underprediction during rising or falling concentrations can indicate that the assumed instantaneous concentration effect or turnover structure is inadequate. Systematic curvature in residuals across concentration may point to an inappropriate Emax curve, an unmodeled effect, or insufficient information to estimate saturation. Check that estimated production remains nonnegative and that fitted parameters yield plausible baseline and equilibrium biomarker levels. Sparse sampling near the transition or data confined to low concentrations may not distinguish a saturable curve from a nearly linear one; observations spanning the transition and upper plateau are more informative about \(EC_{50}\) and \(E_{\max}\).

The Emax function is a useful parsimonious choice when a smooth, saturating response is plausible. The sigmoid Emax form is an alternative when the concentration-effect transition is sharper or more gradual than the basic hyperbola permits. A linear concentration effect can be a local approximation at low concentrations, but it does not impose a finite plateau. These alternatives change the assumed concentration-to-synthesis relationship; they do not change the first-order loss assumption in the model presented here.

A common pitfall is to interpret \(E_{\max}\) as the maximum percentage increase in the biomarker observed at any finite concentration. It is the maximum fractional change in the production rate as \(C\) approaches saturation. Under constant first-order loss, the equilibrium fractional change in biomarker matches it, but a finite concentration generally produces a smaller change, and the biomarker approaches its new equilibrium gradually. Confusing the production rate with the biomarker level, or treating a transient observation as steady state, can therefore lead to incorrect conclusions.

This model is limited when loss itself changes with concentration, when baseline input drifts, or when a delayed or history-dependent drug effect is needed. Such patterns should not be repaired merely by adding a Hill coefficient: \(\gamma\) changes curve steepness, not the model’s mechanism. The concentration data, biomarker time course, and biological interpretation should jointly support the chosen structure.